CN106074496A - Cannabinol compounds application in preparation treatment gout medicine - Google Patents
Cannabinol compounds application in preparation treatment gout medicine Download PDFInfo
- Publication number
- CN106074496A CN106074496A CN201610421213.0A CN201610421213A CN106074496A CN 106074496 A CN106074496 A CN 106074496A CN 201610421213 A CN201610421213 A CN 201610421213A CN 106074496 A CN106074496 A CN 106074496A
- Authority
- CN
- China
- Prior art keywords
- cannabinol
- acid
- fructus cannabis
- cannabinol compounds
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Abstract
The invention discloses cannabinol compounds application in preparation treatment gout medicine.Inventor finds the gout effect that cannabinol compounds tool is the strongest first, hyperuricemia mice serum uric acid level can be significantly reduced, Normal Mouse Serum uric acid level is not made significant difference, can significantly drop the toes swelling that suppression is induced by Monosodium urate, activity is better than allopurinol, and toxic and side effects is little.Present invention also offers the pharmaceutical preparation of cannabinol compounds treatment gout and corresponding pharmaceutical dosage form thereof, with conventional preparation method, the medicine of the various different dosage forms used clinically can be formed in, easy to use.
Description
Technical field
The present invention relates to the cannabinol compounds of extraction new application in medical science from Fructus Cannabis, concretely relate to
Cannabinol compounds application in preparation treatment gout medicine.
Background technology
Goat is the class disease that internal purine metabolic disturbance causes, purine through a series of metabolic alterations, end form
The product become is uric acid.What physiological function uric acid does not has in human body, under normal circumstances, the uric acid 2/3 of internal generation by
Kidney is discharged, and 1/3 is discharged by large intestine.Internal uric acid is to constantly generate and draining, and therefore it remains certain in blood
Concentration.In the synthesis and catabolic process of purine, there is the participation of multiple enzyme, owing to the birth defect metabolism of enzyme occurs disorderly
Disorderly, make the synthesis of uric acid increase or discharge and reduce, all can cause hyperuricemia.When serum Uric Acid Concentration is too high, uric acid i.e. with
The form of sodium salt is deposited in joint, soft tissue, cartilage and kidney, causes the foreign body inflammatory reaction of tissue to become to cause gout
The seed of trouble.As treatment the most thoroughly can cause arthroncus, deformity, stiff, periarticular ecchymosis, tuberosity, concurrent gouty renal calculus, bitterly
Wind renal failure, the life of the internal organs disease threat patients such as gouty coronary heart disease, hyperlipidemia, hypertension, urinary system calculus
The straight termination causing life of life.
Along with our people's growth in the living standard, life-time dilatation, the change (food rich in nucleoprotein of dietary structure
Increase), the increase of overweight people, and the attention degree reinforcement etc. to primary disease, gout is the most no longer the rare disease of compatriots, and it is ill
Rate relatively increased about 15～30 times before 15 years.Gout is apt to occur in middle-aging male, but middle and aged women and young man at present
Sickness rate risen.Age of onset is many more than 50 years old (63%)；In gerontal patient, women sickness rate is higher than man
Property, and sickness rate improves 29% after 60 years old by 60 years old front 7%.CDC up-to-date report display,
The sickness rate of China's gout surpasses the world average level, and whole nation patient with gout is more than seven million people, and whole world goat patient is up to
1.3 hundred million.
The current kind of antigout drug is few, and clinical treatment is mainly with colchicine, nonsteroidal antiinflammatory drug, hormone, promotion
Urate excretion medicine (such as probenecid, sulfinpyrazone and benzbromarone) and suppression uric acid synthetic drug (such as allopurinol) are main.Acute
Stadium mainly applies drink tazettine, nonsteroidal antiinflammatory drug, hormone, and the catabasis mainly applies promotion urate excretion medicine, suppression urine
Acid synthetic drug.These medicines are the most defective in treatment.Weak curative effect, side effect become greatly the bottleneck of its clinical practice, and not
Can life-time service.More common Chinese patent medicine preparations treat pain phoenix, but drug effect is relatively low.So being badly in need of at present grinding
System and exploitation selectivity are strong, have no side effect, efficiently and gout will not be made to produce the anti-gout novel medical of bounce-back after drug withdrawal.
Containing multiple cannabinol compounds in Fructus Cannabis.Cannabinol compounds is a terpenoid phenolic compound,
Being separated to more than 70 kinds, the most more important has: cannabinol, cannabidiol, tetrahydrocannabinol, cannabinol, cannabidiolic acid,
Tetrahydro-cannabinolic acid etc..What the most main and content was the highest is cannabidiol, tetrahydrocannabinol and cannabinol, and it has and disappears
Inflammation, analgesia, preventing or arresting vomiting, antitumor, spasmolytic, anxiety etc. act on.
Summary of the invention
It is an object of the invention to provide the new application of cannabinol compounds, i.e. new opplication in pharmacy.
It practice, the present invention relates to cannabinol compounds application in the medicine of preparation treatment or prevention gout；Institute
In the cannabinol compounds stated, the content of cannabidiol is 0.3%～99.7%, and other compositions are tetrahydrocannabinol, Fructus Cannabis
Phenol, cannabigerol, cannabicyclol, cannabinol, tetrahydro-cannabinolic acid, cannabidiolic acid, cannabigerolic acid, hexahydro time Fructus Cannabis furan
Mixing of one or more in phenolic acid, secondary cannabinol, cannabidivarin CBDV Cannabidivarol, tetrahydrocannabinovarin, Fructus Cannabis chromene and time Fructus Cannabis chromene
Compound.
The invention still further relates to the application in preparation fall blood uric acid medicine of the described cannabinol compounds.
The invention still further relates to the application in preparation treatment or prevention antihyperuricemic disease drug of the described cannabinol compounds.
In order to be more fully understood that the essence of the present invention, pharmacological evaluation and result with cannabinol compounds illustrate below
Its new application in pharmaceutical field.
1, prepare cannabinol compounds, but cannabinol compounds used is not limited to following preparation method obtains
Arrive.
Taking cannabis, leaf, fiber crops bran or three's mixture, after remove impurity, drying, pulverize, CO2 is super faces extraction, precipitation remove impurity
Rear ethanol re-dissolved, lysate is pentane eluting after chromatography, collects eluent, concentrating under reduced pressure, vacuum drying, pulverizes,
Cannabinol compounds.
2, cannabinol compounds powder is taken, standby after diluting with sodium chloride.
3, the cannabinol compounds impact on hyperuricemia mice uric acid is observed with conventional pharmacological testing.
(1) choose body weight 18～22g Kunming mouse 60, male and female half and half, be randomly divided into 6 groups, often group 10, the most normally
Matched group, model group, positive drug allopurinol tablet (40mg/kg) group, cannabinol compounds A, B, C group (20mg/kg).A group is (big
Fiber crops diphenol content 0.3%), B group (cannabidiol content 50%), C group (cannabidiol content 99.7%).
Gastric infusion, 1 time/d, Normal group and model group gavage such as give at capacity distilled water, the continuous 12d.Last is given
Medicine 1h pneumoretroperitoneum injection hypoxanthine 10mg/kg, after 1h, eyeball takes blood, and 3000r/min is centrifuged 10min, takes supernatant and surveys serum
Uric acid content.
Test result indicate that, compare with Normal group, model group mice serum uric acid content is significantly raised, has significance
Difference (P ＜ 0.05), prompting modeling success.After giving cannabinol compounds, compare with model group, cannabinol compounds A,
B, C group all can significantly reduce mice serum uric acid content, and difference has significance (P ＜ 0.05～0.01)；With other purine sheet group
Relatively, cannabinol compounds A, B, C group fall mice serum uric acid content effect is all better than other purine sheet group, and difference has significantly
Property (P ＜ 0.05).Prompting, cannabinol compounds significantly reduces effect, effect to the Mouse Blood uric acid caused by hypoxanthine
It is better than other purine sheet.The results are shown in Table 1.
The impact of the hyperuricemia mice uric acid that hypoxanthine is induced by table 1 cannabinol compounds
| Group | Dosage (mg/Kg) | Serum uric acid concentration (mg/L) |
| Normal control sample | Equal-volume distilled water | 132.12±46.36 |
| Model comparison sample | Equal-volume distilled water | 200.04±46.62<sup>△</sup> |
| Allopurinol tablet group | 40 | 157.48±36.07* |
| Cannabinol compounds A group | 20 | 126.46±38.19*<sup>#</sup> |
| Cannabinol compounds B group | 20 | 116.45±36.13**<sup>#</sup> |
| Cannabinol compounds C group | 20 | 111.02±40.01**<sup>#</sup> |
Note: compare with normal control sample,△P ＜ 0.05, does not compares with model group, * P ＜ 0.05, * * P ＜ 0.01, and not
Fast alcohol sheet group, compares#P ＜ 0.05.
(2) cannabinol compounds impact on the acid of normal mouse retention
Choosing body weight 18～22g Kunming mouse 40, male and female half and half, be randomly divided into 4 groups, often group 10, the most right
According to group, cannabinol compounds A, B, C group (20mg/kg).Gastric infusion, 1 time/d, Normal group and model group gavage give
Deng capacity distilled water, continuous 12d.Last is administered 1h eyeball and takes blood, and 3000r/min is centrifuged 10min, takes supernatant and surveys serum uric acid
Content.
Test result indicate that, compare with Normal group, after giving cannabinol compounds, each group to mice serum uric acid
The equal zero difference of content (P ＞ 0.05).Prompting, normal Mouse Blood uric acid is not made significant difference by cannabinol compounds.The results are shown in Table
2。
The impact on the acid of normal mouse retention of table 2 cannabinol compounds
| Group | Dosage (mg/Kg) | Serum uric acid concentration (mg/L) |
| Normal control sample | Equal-volume distilled water | 132.12±46.36 |
| Cannabinol compounds A group | 20 | 145.85±24.20 |
| Cannabinol compounds B group | 20 | 138.73±27.19 |
| Cannabinol compounds C group | 20 | 127.28±26.55 |
(3) cannabinol compounds causes the impact of rat paw edema to micro-crystal type Monosodium urate crystallization (MSU).
The preparation of MSU: put by 5g uric acid in 1000mL boiling water, adjusts pH to 7.4 with NaOH, is heated to 95 DEG C.Put room temperature bar
Part cools down and is gently mixed, and filters and i.e. obtains MSU, and MSU is placed in 200 DEG C of high temperature sterilizes, faces the used time and is made into physiological saline solution
The suspension of 100mg/mL is standby.
Choose body weight 180～220gWistar male rat 60, be randomly divided into 6 groups, often group 10, i.e. normal control
Group, model group, positive drug allopurinol tablet group (40mg/kg), cannabinol compounds A, B, C group (20mg/kg).Gastric infusion, 1
Secondary/d, Normal group and model group gavage such as give at capacity distilled water, the continuous 15d.After last is administered 1h, in Rat Right metapedes
Plantar subcutaneous injection 0.15mL MSU (100mg/mL) causes inflammation, measures right metapedes sole of the foot Zhou Jing before and after causing inflammation.Observe and measure
Pedal swelling situation and Zhou Jing thereof after 1h, 2h, 3h, 5h, 7h Rat Right the most in the same time after injection, calculate its swelling.The foot sole of the foot
Swelling=(t time Zhou Jing-t0Time Zhou Jing)/t0Time Zhou Jing × 100%.
Result shows, compares with Normal group, and model group rats swelling degree of the paw is significantly raised, has significant difference (P
＜ 0.01), prompting modeling success.Cannabinol compounds compares with model group, and each group all can significantly inhibit rat paw edema,
Difference has significance (P ＜ 0.05, P ＜ 0.01), compares with other purine sheet group, cannabinol compounds group suppression rat paw
Swelling is better than other purine sheet group, and difference has significance (P ＜ 0.05).Prompting, cannabinol compounds is to rat foot caused by MSU
The degree of sole of the foot swelling has obvious inhibitory action, and effect is better than other purine sheet.The results are shown in Table 3.
The impact on rat paw edema rate of table 3 cannabinol compounds
Note: compare with normal control sample,△△P ＜ 0.05, compares with model group, and * P ＜ 0.05, * * P ＜ 0.01, with the most fast
Alcohol sheet group, compares#P ＜ 0.05.
The invention provides with cannabinol compounds as active component, for treating the pharmaceutical preparation of gout.This medicine
Preparation is with cannabinol compounds for effective active composition, and includes other adjuvant components acceptable on pharmaceutics.Institute
The pharmaceutical preparation stated includes oral agents and injection, and wherein oral agents includes capsule, oral liquid, tablet, drop pill, granule etc.,
Injection type includes injection dosage form and freeze-dried powder injection type etc..When preparing oral formulations, available auxiliary type agent can
To be the conventional filler such as starch, dextrin or cyclodextrin, sucrose, stearate.Lyophilized injectable powder can be by aseptic spray dried
Prepared by the methods such as dry, low-temperature vacuum drying, lyophilization.The later stage preparation technology of each preparation and equipment all belong to the normal of pharmaceutical field
Rule technology, this is not construed as limiting by the present invention, therefore not describes in detail at this.
Could be aware that from result above, it is an advantage of the current invention that:
1, cannabinol compounds has been excavated new medical application by the present invention, has opened up a new application.
2, prove that cannabinol compounds has the strongest gout effect by serial experiment, metabolic arthritis can be significantly reduced
Mass formed by blood stasis mice serum uric acid level, does not makes significant difference to Normal Mouse Serum uric acid level, can significantly drop suppression and be lured by Monosodium urate
The toes swelling led, activity and allopurinol are suitable, and toxic and side effects is little.Cannabinol compounds has significantly treatment and prevention
Wind action bitterly.
3, the cannabinol compounds safety non-toxic of the present invention, pharmacological action is strong, imply that good prospect in medicine.
4, the present invention products material abundance, inexpensive, have no toxic and side effects, preparation technology is simple, and can make mouth
Oral dosage form, injection type, tablet etc., easy to use, injection can make intramuscular injection and intravenous injection.
Detailed description of the invention
Below by embodiment, the present invention is described in further detail, but embodiment is not to the technology of the present invention side
The restriction of case.
Embodiment 1
Taking cannabis, leaf, after remove impurity, drying, pulverize, CO2 is super faces extraction, and ethanol re-dissolved after precipitation remove impurity is dissolved
Liquid is pentane eluting after chromatography, collects eluent, concentrating under reduced pressure, vacuum drying, pulverizes, obtain cannabinol compounds.
Take cannabinol compounds 100 grams (crossing 80 mesh sieves), add 60 grams of microcrystalline Cellulose, cross 80 mesh sieve three times, mixing
Uniformly, spray into 95% ethanol solution, soft material processed, cross 40 mesh sieves and pelletize, 60 DEG C of dry half an hour, be sub-packed in 3# capsule, plastic-aluminum
Composite packaging, makes capsule.
Embodiment 2
Taking cannabis, leaf, the mixture of fiber crops bran, after remove impurity, drying, pulverize, CO2 is super faces extraction, second after precipitation remove impurity
Alcohol re-dissolved, lysate is pentane eluting after chromatography, collects eluent, concentrating under reduced pressure, vacuum drying, pulverizes, obtain Fructus Cannabis
Phenolic compound.
Taking cannabinol compounds powder, admixture doses 5～the dried starch of 20% and 1～the magnesium stearate of 5%, through mixed
Close, pelletize, be dried, tabletting, make tablet.
Embodiment 3
Repeat embodiment 2, have following difference: take the anti-of cannabinol compounds powder, addition sucrose water and convention amount
Rotten agent, the adjuvant such as stabilizer.Filtration, sterilizing, be distributed in 10mL bottle, make oral liquid.
Embodiment 4
Repeat embodiment 2, have following difference: take cannabinol compounds powder, add water for injection and dissolve, add
2.0 ‰ activated carbons, stirring, filter, continue, with 0.45 μm, 0.22 μm microporous filter membrane classified filtering, to supplement water for injection, be sub-packed in
In cillin bottle, lyophilization, recharge high-purity nitrogen, jump a queue, gland, packaging, make injection.
Claims (3)
1. cannabinol compounds application in the medicine of preparation treatment or prevention gout, in described cannabinol compounds
The content of cannabidiol is 0.3%～99.7%, and other compositions are tetrahydrocannabinol, cannabinol, cannabigerol, cannabicyclol,
Cannabinol, tetrahydro-cannabinolic acid, cannabidiolic acid, cannabigerolic acid, hexahydro time Fructus Cannabis furan phenolic acid, secondary cannabinol, secondary Fructus Cannabis
The mixture of one or more in diphenol, tetrahydrocannabinovarin, Fructus Cannabis chromene and time Fructus Cannabis chromene.
2. cannabinol compounds application in preparation fall blood uric acid medicine, cannabidiol in described cannabinol compounds
Content be 0.3%～99.7%, other compositions are tetrahydrocannabinol, cannabinol, cannabigerol, cannabicyclol, cannabinol,
Tetrahydro-cannabinolic acid, cannabidiolic acid, cannabigerolic acid, hexahydro time Fructus Cannabis furan phenolic acid, secondary cannabinol, cannabidivarin CBDV Cannabidivarol, tetrahydrochysene
The mixture of one or more in secondary cannabinol, Fructus Cannabis chromene and time Fructus Cannabis chromene.
3. cannabinol compounds application in preparation treatment or prevention antihyperuricemic disease drug, described cannabinoids chemical combination
In thing, the content of cannabidiol is 0.3%～99.7%, and other compositions are tetrahydrocannabinol, cannabinol, cannabigerol, Fructus Cannabis ring
Phenol, cannabinol, tetrahydro-cannabinolic acid, cannabidiolic acid, cannabigerolic acid, hexahydro time Fructus Cannabis furan phenolic acid, secondary cannabinol, secondary greatly
The mixture of one or more in fiber crops diphenol, tetrahydrocannabinovarin, Fructus Cannabis chromene and time Fructus Cannabis chromene.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610421213.0A CN106074496A (en) | 2016-06-14 | 2016-06-14 | Cannabinol compounds application in preparation treatment gout medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610421213.0A CN106074496A (en) | 2016-06-14 | 2016-06-14 | Cannabinol compounds application in preparation treatment gout medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106074496A true CN106074496A (en) | 2016-11-09 |
Family
ID=57846687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610421213.0A Pending CN106074496A (en) | 2016-06-14 | 2016-06-14 | Cannabinol compounds application in preparation treatment gout medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074496A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019052303A1 (en) | 2017-09-15 | 2019-03-21 | 汉义生物科技（北京）有限公司 | Composition containing cannabidiol and/or cannabidivarin and application of composition in treatment of dysmenorrhea |
| CN110064030A (en) * | 2019-05-30 | 2019-07-30 | 厦门梓素生物科技有限公司 | One kind extract for treating gouty arthritis medicinal application of CBD containing cannabidiol |
| CN110632224A (en) * | 2019-09-16 | 2019-12-31 | 福建省中科生物股份有限公司 | Establishment method of hemp plant fingerprint spectrum |
| CN111212638A (en) * | 2017-09-08 | 2020-05-29 | 西卡恩治疗公司 | Compositions comprising cannabinoids and spilanthol |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| US11084770B2 (en) | 2016-12-07 | 2021-08-10 | Treehouse Biotech, Inc. | Cannabis extracts |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6949582B1 (en) * | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
| WO2010126501A1 (en) * | 2009-04-29 | 2010-11-04 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
-
2016
- 2016-06-14 CN CN201610421213.0A patent/CN106074496A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6949582B1 (en) * | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
| WO2010126501A1 (en) * | 2009-04-29 | 2010-11-04 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
Non-Patent Citations (1)
| Title |
|---|
| 魏平等: "《临床速查掌中宝丛书-内分泌科临床速查掌中宝》", 31 January 2015 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11084770B2 (en) | 2016-12-07 | 2021-08-10 | Treehouse Biotech, Inc. | Cannabis extracts |
| CN111212638A (en) * | 2017-09-08 | 2020-05-29 | 西卡恩治疗公司 | Compositions comprising cannabinoids and spilanthol |
| WO2019052303A1 (en) | 2017-09-15 | 2019-03-21 | 汉义生物科技（北京）有限公司 | Composition containing cannabidiol and/or cannabidivarin and application of composition in treatment of dysmenorrhea |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| CN110064030A (en) * | 2019-05-30 | 2019-07-30 | 厦门梓素生物科技有限公司 | One kind extract for treating gouty arthritis medicinal application of CBD containing cannabidiol |
| CN110632224A (en) * | 2019-09-16 | 2019-12-31 | 福建省中科生物股份有限公司 | Establishment method of hemp plant fingerprint spectrum |
| CN110632224B (en) * | 2019-09-16 | 2022-02-15 | 福建省中科生物股份有限公司 | Establishment method of hemp plant fingerprint spectrum |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106074496A (en) | Cannabinol compounds application in preparation treatment gout medicine | |
| CN102670864B (en) | Medicine composition with antioxidant function for treating cardiovascular and cerebrovascular diseases and sugar diabetes | |
| CN105997985A (en) | Application of marihuana extract in preparation of gout treating medicine | |
| CN106074465A (en) | Cannabinol compounds application in preparation treatment gouty arthritis medicine | |
| CN109674958A (en) | A kind of Chinese medicine composition and its preparation method and application with anti-trioxypurine | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| CN106074493A (en) | The application in preparation treatment gouty arthritis medicine of a kind of Fructus Cannabis extract | |
| CN106074463A (en) | Cannabidiol application in preparation treatment gouty arthritis medicine | |
| CN102058631B (en) | Seabuckthorn leaf extract preparation and preparation method thereof | |
| US20170028007A1 (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
| CN101278928A (en) | Medicament composition containing levocarnitine or its derivatives and use thereof | |
| CN106074464A (en) | Cannabidiol application in preparation treatment gout medicine | |
| CN101309692A (en) | Application of curbitacin or curbitacin combination in leucocyte increasing medicament preparation | |
| CN106389535A (en) | Application of industrial hemp cannaboid in preparing gout treating medicines | |
| CN104688760A (en) | Pharmaceutical composition composed of saikoside A and taurine and use thereof | |
| JP2021512997A (en) | Separated windproof polysaccharides and their uses | |
| CN102526157B (en) | Application of safflower extract to prevention or treatment of neurodegeneration disease | |
| WO2009062374A1 (en) | The pharmaceutical use of liquiritigenin for preparing medicine for treating neurodegenerative diseases | |
| EP2124980A1 (en) | Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases | |
| JP2019501912A (en) | Use of citrus extract and isoacteoside in muscle protection | |
| CN1718566A (en) | Ferulaic acid and its sodium salt used for preventing and treating senile dementia medicine | |
| CN1907432A (en) | Application of polysaccharide from the Gastrodia elata Blume in health caring stuff and medicine | |
| CN1762341A (en) | Salvianolic acid compound for treating cardiovascular and cerebrovascular disease and liver disease, and application thereof | |
| CN106581109A (en) | Cerebral thrombosis treating pharmaceutical composition | |
| CN1899329A (en) | Medicinal composition with blood fat reducing function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Chenfeng Inventor after: Hu Chengyue Inventor before: Chen Tianrui Inventor before: Hu Chengyue |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161109 |